<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Mindmaze Therapeutics Holding Sa — News on 6ix</title>
    <link>https://6ix.com/company/mindmaze-therapeutics-holding-sa</link>
    <description>Latest news and press releases for Mindmaze Therapeutics Holding Sa on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 12 Mar 2026 07:44:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/mindmaze-therapeutics-holding-sa" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d6c4cebeedb30cb60001b5.webp</url>
      <title>Mindmaze Therapeutics Holding Sa</title>
      <link>https://6ix.com/company/mindmaze-therapeutics-holding-sa</link>
    </image>
    <item>
      <title>MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale</title>
      <link>https://6ix.com/company/mindmaze-therapeutics-holding-sa/news/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale</link>
      <guid isPermaLink="true">https://6ix.com/company/mindmaze-therapeutics-holding-sa/news/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale</guid>
      <pubDate>Thu, 12 Mar 2026 07:44:00 GMT</pubDate>
      <description>GENEVA, March 12, 2026--MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics, or the Company), a global leader in brain technology and precision neurotherapeutics, today announced the appointment of Zach Henderson as Chief Executive Officer. Mr. Henderson joins at a pivotal inflection point as the Company invests in scaling its existing commercial presence, focused on accelerating adoption of its FDA-cleared platform in the United States to address the widening supply-demand gap i</description>
    </item>
    <item>
      <title>MindMaze Therapeutics Provides Corporate Update and Publishes March 2026 Investor Presentation</title>
      <link>https://6ix.com/company/mindmaze-therapeutics-holding-sa/news/mindmaze-therapeutics-provides-corporate-update-and-publishes-march-2026-investor-presentation</link>
      <guid isPermaLink="true">https://6ix.com/company/mindmaze-therapeutics-holding-sa/news/mindmaze-therapeutics-provides-corporate-update-and-publishes-march-2026-investor-presentation</guid>
      <pubDate>Tue, 03 Mar 2026 07:45:00 GMT</pubDate>
      <description>GENEVA, CH / ACCESS Newswire / March 3, 2026 / MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics, or the Company), a commercial-stage company delivering evidence-based, precision digital treatments for neurological diseases, today ...</description>
    </item>
  </channel>
</rss>